Comprehensive review of safety in Experimental Human Pneumococcal Challenge

Author:

Robinson Ryan E.ORCID,Myerscough Christopher,He Nengjie,Hill Helen,Shepherd Wendi A.ORCID,Gonzalez-Dias PatriciaORCID,Liatsikos Konstantinos,Latham SamuelORCID,Fyles FredORCID,Doherty Klara,Hazenberg Phoebe,Shiham Fathimath,Mclenghan Daniella,Adler Hugh,Randles Vicki,Zaidi Seher,Hyder-Wright Angela,Mitsi Elena,Burhan Hassan,Morton BenORCID,Rylance Jamie,Lesosky MaiaORCID,Gordon Stephen B.ORCID,Collins Andrea M.,Ferreira Daniela M.

Abstract

Introduction Experimental Human Pneumococcal Challenge (EHPC) involves the controlled exposure of adults to a specific antibiotic-sensitive Streptococcus pneumoniae serotype, to induce nasopharyngeal colonisation for the purpose of vaccine research. The aims are to review comprehensively the safety profile of EHPC, explore the association between pneumococcal colonisation and frequency of safety review and describe the medical intervention required to undertake such studies. Methods A single-centre review of all EHPC studies performed 2011–2021. All recorded serious adverse events (SAE) in eligible studies are reported. An unblinded meta-analysis of collated anonymised individual patient data from eligible EHPC studies was undertaken to assess the association between experimental pneumococcal colonisation and the frequency of safety events following inoculation. Results In 1416 individuals (median age 21, IQR 20–25), 1663 experimental pneumococcal inoculations were performed. No pneumococcal-related SAE have occurred. 214 safety review events were identified with 182 (12.85%) participants presenting with symptoms potentially in keeping with pneumococcal infection, predominantly in pneumococcal colonised individuals (colonised = 96/658, non-colonised = 86/1005, OR 1.81 (95% CI 1.28–2.56, P = <0.001). The majority were mild (pneumococcal group = 72.7% [120/165 reported symptoms], non-pneumococcal = 86.7% [124/143 reported symptoms]). 1.6% (23/1416) required antibiotics for safety. Discussion No SAEs were identified directly relating to pneumococcal inoculation. Safety review for symptoms was infrequent but occurred more in experimentally colonised participants. Most symptoms were mild and resolved with conservative management. A small minority required antibiotics, notably those serotype 3 inoculated. Conclusion Outpatient human pneumococcal challenge can be conducted safely with appropriate levels of safety monitoring procedures in place.

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference24 articles.

1. Human infection studies: Key considerations for challenge agent development and production;S Balasingam;Wellcome Open Res,2022

2. World Health Organisation. Human Challenge Trials for Vaccine Development: regulatory considerations. Available at https://www.who.int/biologicals/expert_committee/Human_challenge_Trials_IK_final.pdf: World Health Organisation;2016. (Accessed 15/08/22).

3. Typhoidal Salmonella human challenge studies: ethical and practical challenges and considerations for low-resource settings;M Raymond;Trials,2019

4. The immune response to pneumococcal proteins during experimental human carriage;TL McCool;J Exp Med,2002

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3